MAPT and Atypical behavior: Atomoxetine, an approved NE transporter inhibitor, not only reduces Tau and phosphorylated Tau in cerebrospinal fluid, but also normalises a group of protein biomarkers associated with synaptic function, brain metabolism and immunity, alleviating mild behavioural disorders [117].